
ARIEL 4: A study of rucaparib versus chemotherapy in BRCA positive ovarian cancer
The aim of the trial is to fully understand the benefits of a PARP inhibitor versus standard chemotherapy for BRCA-positive women who have had two previous treatments. Drugs involved in this trial: rucaparib, a PARP inhibitor paclitaxel, a standard chemotherapy drug carboplatin or cisplatin, standard chemotherapy drugs. Women in t…